HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 8, August 2016 – Novel Technologies for Antibody Drug Discovery in Japan       » Global Experts Convene to Discuss China's Plan for Diabetes Prevention and Rehabilitation in 2016       » Butterflies Offer Climate Scientists Ecological Insights       » Thermal Stability of Camelid Single Domain VHH Antibody       » That Gut Feeling: How A Healthy Digestive System Has Everything To Do With It       » World Heart Day - At the Heart of Health      
INSIDE INDUSTRY
AbbVie expands manufacturing presence with US$320 million investment in Singapore

AbbVie Inc. has invested US$320 million [approximately S$400 million] to establish operations in Singapore for small molecule and biologics active drug substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie's oncology and immunology pipeline to serve markets globally.

The investment will establish the first manufacturing presence in Asia by AbbVie. Other AbbVie operations in Asia include research and development (R&D) functions in Tokyo, Japan and Shanghai, China, as well as commercial operations throughout the region. AbbVie's existing presence in Singapore includes 120 personnel, supporting commercial operations, global R&D and general operations.

"As Asia's fastest-growing bio-cluster, Singapore is an ideal location to expand our manufacturing network while maintaining rigorous standards of quality and delivery for the patients we serve around the world," said Azita Saleki-Gerhardt, Ph.D., Senior Vice President, Operations, AbbVie. "Our presence in Singapore will help assure geographic balance and continuity of product supply as well as increased capacity to deliver on our growing biologics and small molecule product pipeline."

"We are very pleased that Singapore will host AbbVie's first manufacturing facility in Asia. This investment is a testament of Singapore's strong biologics manufacturing capabilities. To support the continued growth of this sector, Singapore will be investing heavily in human capital development, and new programs will be put in place to train biologics manufacturing talent ahead of demand," said Kevin Lai, Director, Biomedical Sciences of the Singapore Economic Development Board.

The investment is expected to result in additional headcount of more than 250 new employees. AbbVie anticipates the new facility will be fully operational by 2019.

Click here for the complete issue.

NEWS CRUNCH  
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
news NUS Student Clinches Top Prize at National Smart Mapping Competition with Cutting-Edge Food Security Solution
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Evidence-based TCM
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy